Savvy Trades and Investments

[researcher59]

JAZZ (117) looks cheap on a PE basis but the company has lots of debt and Q4 product sales were flat y/y although royalty revenue helped total revenue. I think a lot depends upon their new drug pipeline. If they have some successful new drugs, the stock is undervalued, but otherwise they may struggle to grow revenues as in Q4. Also the stock is basically unchanged over the past decade, badly underperforming the broader market. Maybe that will change in the future, but it's a poor track record. It may be a better stock to trade than hold. I'll be interested in seeing the Q1 results in early May.